Citations

Clear

224 citation(s) found for "Su, Jen-Jen".

Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers
Peniche, Paola Zinser, Baytar, Doga Kahramangil, Jambunathan, Sree , Jan, Yu Jen , Hsieh, Ronan, Krauß, J. , Veenstra, Christine M, Şahin, İbrahim Halil , Krauss, John C. , Aksu, Muhammed Dogukan, Veenstra, Christine M , Sahin, Ibrahim Halil , Aksu, Murat , Hsieh, Ronan W. , Rahman, Shafia

Mayo Clinic

The Oncologist | July 30, 2026 | Volume: 31 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyag302 | PMID 42536421 Get It

Abstract Background Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. Patients and methods We analyzed cBioPortal data from 4348 CRC patients with available ERBB2/HER2 profiling. Clinicodemographic features, microsatellite instability (MSI), tumor mutational burden, and alterations in 94 cancer-associated genes were evaluated using chi-square/Fisher’s exact test, Kruskal–Wallis test, and hierarchical clustering. Results ERBB2/HER2 putative driver mutations were identified in 95 patients (2.2%), amplifications in 87 (2.0%), and wild-type status in 4166 (95.8%). In the overall cohort, ERBB2/HER2-mutated tumors demonstrated significant KRAS enrichment (50.5%) compared to wild-type (37.7%; P = .014) and amplified tumors (18.4%; P < .001), alongside MSI enrichment (37.2% vs 1.6%; P < .001), elevated tumor mutational burden, and right-sided predominance. ERBB2/HER2-mutated tumors also showed broad driver co-alterations largely reflecting their MSI background. In contrast, ERBB2/HER2-amplified tumors exhibited left-sided predominance, with microsatellite stable (MSS)-restricted analyses revealing selective mutual exclusivity with KRAS (Log2 OR = −1.58; q = 0.019) and TP53 co-occurrence (Log2 OR = 2.04; q = 0.019). Hierarchical clustering confirmed that mutated and amplified tumors consistently occupy separate clusters across anatomical sites. Conclusion ERBB2/HER2 mutations and amplifications represent molecularly and clinically distinct subgroups. ERBB2/HER2-mutated tumors are characterized by an MSI-enriched, hypermutated background with frequent concurrent KRAS alterations, whereas amplified tumors exhibit selective KRAS mutual exclusivity and TP53 co-occurrence. These exploratory findings support alteration-specific therapeutic strategies in CRC.
The value of a neuroanesthesiology division
Gruenbaum, Benjamin F., Uejima, Jamie L., Yang, Jen-Ting , Gruenbaum, Benjamin F. , Gruenbaum, Benjamin Fredrick

Mayo Clinic

Current Opinion in Anaesthesiology | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/aco.0000000000001694 | PMID 42515830 Get It

Purpose of review To review the clinical, educational, academic, and institutional value of a dedicated neuroanesthesiology division beyond its practical role in scheduling neurosurgical and neurointerventional cases. Recent findings Neuroanesthesiology has matured into a recognized subspecialty with dedicated societies, journals, fellowship pathways, educational milestones, and defined research priorities. Recent observational studies suggest that dedicated neuroanesthetic care, formal fellowship training, and surgeon–anesthesiologist dyad familiarity may be associated with fewer neurologic complications, lower in-hospital morbidity, shorter length of stay, and reduced admission costs in high-acuity neurosurgical populations. Concurrently, quality improvement reports identify recurring challenges in medication management, communication, documentation, and equipment readiness that a focused division is well positioned to address. For instance, division-led initiatives at select institutions have successfully integrated The SNACC Neuroanesthetic Emergencies Critical Event Treatment Guides and Cognitive Aids into clinical and educational workflows. Cultivating this subspecialty identity may be a protective factor against clinician burnout. However, current evidence remains largely retrospective and context-dependent. Summary: A neuroanesthesiology division can provide infrastructure for clinical expertise, care pathways, simulation-based education, mentorship, research, quality improvement, and collaboration with neuroscience programs. Its core value lies in creating a reliable structure that supports both neuroanesthesiologists and general anesthesiologists caring for neurologically vulnerable patients.
Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed
Blackwell, Thomas W., Kachuri, Linda , Castaldi, Peter J. , Cho, Michael H. , Christenson, Stephanie A. , Durda, Peter , Gabriel, Stacey , Hersh, Craig P. , Huntsman, Scott , Hwang, S.-J., Joehanes, Roby, Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching‐Ti , Liu, Yongmei , Mak, Angel C. Y. , Manichaikul, Ani , Paik, David T. , Saferali, Aabida , Smith, Joshua D. , Taylor, Kent D. , Wang, Jiongming , Weinstock, Joshua S. , Weiss, Jeffrey, Wheeler, Heather E. , Zhou, Ying , Zoellner, Sebastian, Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R.G. , Ortega, Victor E. , Johnson, Craig , Gan, Weiniu , Abecasis, Gonçalo , Nickerson, Deborah A. , Ardlie, Kristin G., Woodruff, Prescott G. , Bowler, Russell P. , Meyers, Deborah A. , Reiner, Alex, Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S. , Silverman, Edwin K. , Rich, Stephen S., Heard‐Costa, Nancy L. , Tang, Hua, Rotter, Jerome I. , Smith, Albert V. , Aguet, François, Scott, Laura J. , Raffield, Laura M. , Parker, Stephen C.J. , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan, Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Pankow, James, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric, Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng, Rich, Stephen S. , Pankow, James S. , Reiner, Alex P. , Aguet, François , Johnson, W. Craig , Ardlie, Kristin , Orchard, Peter , Kachuri, Linda , Castaldi, Peter J , Cho, Michael H , Christenson, Stephanie A , Durda, Peter , Hersh, Craig P , Huntsman, Scott , Hwang, Seungyong , Joehanes, Roby , Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching-Ti , Liu, Yongmei , Mak, Angel C Y , Manichaikul, Ani W , Paik, David T , Smith, Joshua D , Taylor, Kent D , Tracy, Russell P , Wang, Jiongming , Wang, Mingqiang , Weinstock, Joshua S , Weiss, Jeffrey , Wheeler, Heather E , Zhou, Ying , Zöllner, Sebastian , Wu, Joseph C , Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R G , Ortega, Victor E , Johnson, W Craig , Gan, Weiniu , Gupta, Namrata , Ardlie, Kristin , Woodruff, Prescott G , Bowler, Russell P , Reiner, Alexander P , Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S , Silverman, Edwin K , Rich, Stephen S , Heard-Costa, Nancy , Tang, Hua , Rotter, Jerome I , Smith, Albert V , Levy, Daniel , Aguet, François , Scott, Laura J , Raffield, Laura M , Parker, Stephen C J , Pankow, James S , Tracy, Russell P. , Wu, Joseph C. , Larson, Martin G. , Cupples, L. Adrienne , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan , Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric , Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng

Mayo Clinic

Science | July 16, 2026 | Volume: 393 | Issue: 6808 | Pages: No page available

10.1126/science.adx2989 | PMID 42462027 Get It

Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.
Myocardial Perfusion and Fluorodeoxyglucose Uptake Patterns in Cardiac Sarcoidosis Stratified by Diagnostic Category and Systemic Involvement
Davison, Jen, Elwazir, Mohamed, AbouEzzeddine, Omar, Bois, John, Giudicessi, John, Chareonthaitawee, Panithaya, Cooper, Leslie, Rosenbaum, A., Davison, Jenna , Davison, Jenna M , Sykora, Daniel , Tersalvi, Gregorio , Elwazir, Mohamed Y. , AbouEzzeddine, Omar F. , Bois, John P. , Giudicessi, John R. , Chareonthaitawee, Panithaya

Mayo Clinic

Circulation Journal | June 25, 2026 | Volume: 90 | Issue: 11 | Pages: 1745-1747

10.1253/circj.cj-26-0423 | PMID 42366066 Get It

Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Merchan, Jaime R. , Patel, Manish R. , Cripe, Timothy P. , Old, Matthew , Boughton, Jen , Marcano, Rosa M. Diaz , Peng, Kah-Whye , Russell, Luke, Wiegert, Erol , Bexon, Alice S. , Powell, Steven , Old, Matthew O , Diaz Marcano, Rosa M , Russell, Stephen J , Russell, Luke , Packiriswamy, Nandakumar , Wiegert, Erol , Bexon, Alice S , Powell, Steven F

Mayo Clinic

Cancer Research Communications | June 22, 2026 | Volume: 6 | Issue: 8 | Pages: 1862-1874

10.1158/2767-9764.crc-25-0803 | PMID 42330318 Get It

Abstract Purpose: VV1 is designed to induce selective oncolysis of tumor cells and amplify cellular antitumor immune responses. This open-label, phase I, multicenter clinical trial assessed the safety and tolerability of VV1 monotherapy administered intratumorally or intravenously or administered intravenously in combination with avelumab. Patients and Methods: Patients with advanced solid tumors received intratumoral (n = 27) or intravenous VV1 monotherapy (n = 33) or intravenous VV1 plus avelumab (n = 16). Infusion durations (15–180 minutes) and viral dose (1.7 × 1010 or 1 × 1011 TCID50) were also evaluated. Study objectives included VV1 safety and tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy, and immune responses. Results: Intratumoral and intravenous VV1 were well tolerated, and injection reactions were infrequent. The most common adverse events of any grade related to VV1 were cytokine release syndrome (58%), fatigue (33%), and decreased lymphocyte count (32%). Virus infection of tumors was confirmed by NIS imaging and increases in serum levels of virally encoded interferon-β (IFNβ). Histologic tumor analysis at 28 days after intratumoral VV1 administration indicated increases in tumor-infiltrating immune cells. Two durable partial responses were recorded: a patient with pheochromocytoma after one intravenous dose of VV1 and a patient with thymic cancer in the combination arm. Stable disease was observed in 17 of 49 patients (34.7%) who received intravenous VV1. Conclusions: This first-in-human study demonstrates that intratumoral or intravenous VV1 administration had an acceptable safety profile as monotherapy and intravenously in combination with avelumab. There is preliminary antitumor activity. Intratumoral VV1 plus cemiplimab is now showing promise in the neoadjuvant setting. Significance: VV1 is a tumor-selective oncolytic vesicular stomatitis virus engineered to express IFNβ and the thyroidal NIS reporter gene. In this phase I study, we have demonstrated that a single administration of VV1, as a monotherapy or with an immune checkpoint inhibitor is safe, infects tumor lesions resulting in intratumoral infiltration of immune cells, and exhibits early signs of antitumor activity in patients with advanced unresectable and metastatic solid tumors.
Efficacy and safety profile of volume-staged stereotactic radiosurgery for ruptured, large pediatric arteriovenous malformations: a multicenter cohort analysis
Tos, Salem M., Hajikarimloo, Bardia, Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Eldin, Reem Emad, Lunsford, L Dade, Niranjan, Ajay, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Martínez‐Álvarez, Roberto , Hallan, David R , Fritch, Chanju, Jareczek, Francis, Sciscent, Bao Y., Mathieu, D, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, Ching-Jen, Esquenazi, Y., Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Xu, Zhiyuan, Sheehan, Jason P., Shinya, Yuki , Tos, Salem M , Hajikarimloo, Bardia , Mantziaris, Georgios , Chan, Jason , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Meng, Ying , Martinez-Álvarez, Roberto, Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M., Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.1.peds25593 | PMID 42284606 Get It

OBJECTIVE Ruptured, large pediatric arteriovenous malformations (AVMs) pose a significant management challenge due to high rerupture risk and the morbidity of conventional treatments. Volume-staged stereotactic radiosurgery (VS-SRS) has emerged as an alternative; however, evidence for its use in this specific population is limited. This study aimed to evaluate the long-term efficacy and safety of VS-SRS for ruptured, large AVMs in a dedicated pediatric cohort. METHODS This international, multicenter, retrospective cohort study from 21 centers analyzed outcomes for 42 pediatric patients (age < 18 years) with previously ruptured, large AVMs treated with VS-SRS. The primary outcome was complete AVM obliteration, and secondary outcomes included post-SRS hemorrhage, radiation-induced changes (RICs), and favorable outcome. Favorable outcome in this study was defined as obliteration without post-SRS hemorrhage or permanent RIC. RESULTS At the initial SRS, the median patient age was 14.5 years, and the median AVM volume was 15.0 cm 3 ; most AVMs were high grade (Spetzler-Martin grades IV and V). With a median follow-up of 41.5 months, complete AVM obliteration was achieved in 21 patients (50.0%). The cumulative obliteration rate was 37% at 5 years and 56% at 10 years. Patients with a nidus volume of ≤ 10 cm 3 had significantly higher cumulative obliteration rates than those with a nidus volume > 10 cm 3 (log-rank test, p = 0.021). Similarly, patients treated with a prescription dose > 17 Gy showed significantly higher cumulative obliteration rates compared to those treated with a dose ≤ 17 Gy (log-rank test, p = 0.012). The cumulative 5-year incidences of hemorrhage and RICs following VS-SRS were 19% and 7%, respectively. In multivariable analysis, only larger total AVM volume was an independent predictor of a lower likelihood of favorable outcome (hazard ratio 0.89, 95% CI 0.80–0.99; p = 0.036). CONCLUSIONS In this multicenter pediatric cohort, VS-SRS for ruptured, large AVMs provides a reasonable chance of long-term obliteration, but generally acceptable risks of post-SRS hemorrhage and RICs exist. VS-SRS should be considered as an option for pediatric patients with large, ruptured AVMs.
Trans-ancestry genome-wide association meta-analysis of antidepressant response to selective serotonin reuptake inhibitors in clinical studies of depression
Hu, Ke , Lo, Chris Wai Hang , Awasthi, Swapnil , Pain, Oliver , Singh, Madhurbain , Ahn, Yeeun , Baune, Bernhard T, Biernacka, Joanna M, Choi, Hong , Czamara, D , Domschke, Katharina, Fabbri, Chiara, Ising, Marcus, Jang, Yoonjeong , Kim, Doh Kwan , Kim, Dongjun, Lee, Byung-Chul, Lewis, Glyn, Lim, S-A , Liu, Yu-Li, Myung, Woojae, Perroud, Nader, Serretti, Alessandro, Uher, Rudolf, Weinshilboum, Richard M. , Won, Hong-Hee, Lewis, Cathryn M. , Hu, Ke , Ripke, Stephan , Coleman, Jonathan Ri , Lewis, Cathryn M , Aitchison, Katherine Jean , Baune, Bernhard , Biernacka, Joanna M. , Bondolfi, Guido , Carrillo‐Roa, Tania , Domschke, Katharina , Hamilton, Steven P. , Ising, Marcus , Kato, Masaki , Lewis, Glyn , Liu, Yu‐Li , Myung, Woojae , Tsai, Shih‐Jen , Uher, Rudolf , Weinshilboum, Richard M. , Won, Hong‐Hee

Mayo Clinic

No container title available | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.03.26354703 | PMID 42282178 Get It

Abstract Antidepressants are widely prescribed for major depressive disorder, yet only one-third of patients achieve remission after initial treatment. Previous genome-wide association studies (GWAS) of clinically assessed antidepressant response combined multiple antidepressant classes, potentially obscuring class-specific effects. This study focused on selective serotonin reuptake inhibitors (SSRIs), often first-line due to better tolerability. Data from 15 cohorts across four ancestries were integrated: European (N = 3887; 11 studies), East Asian (N = 1068; 4), African (N = 277; 1), and Admixed American (N = 250; 1). GWAS of non-remission and percentage improvement were conducted within cohorts, followed by ancestry-specific meta-analyses and trans-ancestry meta-regression. Single nucleotide polymorphism (SNP)-based heritability was estimated in European samples. Polygenic scores were used for leave-one-out prediction and to assess shared genetic architecture with psychiatric traits. Gene-level and gene-set enrichment analyses were also performed. No genome-wide significant variants were identified for either outcome in any ancestry-specific or trans-ancestry analyses. However, trans-ancestry meta-regression yielded eight independent loci with suggestive associations (p < 1 × 10 −5 ) for non-remission and 17 for percentage improvement. Gene-set analyses revealed nominal enrichment of the serotonergic synapse pathway for non-remission. SNP-based heritability estimates were not significantly different from zero for either outcome. Better SSRI response was nominally associated with lower genetic predisposition to major depressive disorder, post-traumatic stress disorder, and schizophrenia. This study represents the largest trans-ancestry GWAS of SSRI response, highlighting emerging biological signals. Limited power emphasises the need for larger and ancestrally diverse cohorts to better characterise the genetic architecture of antidepressant response.
Phase 2 study of intratumoral oncolytic VV1 plus cemiplimab: Simon's stage 1 results from head and neck squamous cell carcinoma (HNSCC) cohort.
Powell, Steven , Nguyen, Anna C., Bayne, Harry E. Fuentes, Price, Katharine A. , Kern, Ryan, Fazer-Posorske, Casey, Anderson, D K, Baral, Binav, Boughton, Jennifer, Russell, Luke, Wiegert, Erol , Lowy, Israel , Seebach, Frank, Bexon, Alice, McGarrah, Patrick W. , Adamo, Daniel A. , Kern, Ryan , Fazer-Posorske, Casey , Boughton, Jen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18026 Get It

e18026 Background: Immune checkpoint inhibitor (ICI) therapy is part of standard of care first-line therapy for recurrent or metastatic (R/M) HNSCC. However, less than 20% of patients (CPS ≥1) have an objective response to ICI monotherapy, and most tumors progress within ~3 months. We sought to improve the proportion of patients who benefit from a chemotherapy-free regimen by combining intratumoral (IT) VV1 oncolytic virus (VSV-IFNβ-NIS) injections with the anti-PD-1 antibody, cemiplimab. We report a pre-planned analysis of Simon's stage 1 results. Methods: We activated a phase 2 study testing the efficacy of first line IT VV1 plus cemiplimab in 1 st line patients with R/M HNSCC. A Simon's two-stage design was employed whereby 10 patients would be accrued in stage 1, and if 3 or more responses were observed, 12 additional patients would be accrued for stage 2. The primary endpoint was objective response rate (ORR) per investigator (RECIST 1.1). Eligible patients had untreated R/M HNSCC from primary oropharynx, oral cavity, hypopharynx, or larynx sites with CPS ≥1. Patients had to have at least one measurable lesion amenable to IT injection. Treatment comprised of IT injections to 1-5 lesions of oncolytic VV-1 virus and IV cemiplimab 350 mg on day 1, repeated every 21 days. Each lesion could be injected 3 times; a 4th injection was allowed if a partial response (PR) was achieved after 3 injections. Cemiplimab could be continued for up to 2 years until progression or unacceptable toxicity. Results: Patient and tumor characteristics, as well as efficacy and toxicity are summarized in the table below. Ten patients were treated at the time of Stage 1 analysis, with 3 showing a confirmed PR for ORR of 30%. Responder CPS scores were 45, 12 and 20%. Two of the responders subsequently showed progression after 6.2 and 9.9 months, the third has maintained PR at 7.7 months to date. Eight of 10 patients showed decrease in the sum of target lesion size (mean decrease of 16%; range -57 to 77%). One grade 2 event of ICI nephritis resolved with corticosteroid treatment. Conclusions: Three patients showed confirmed PR by RECIST 1.1 in Simon's stage 1, meeting criteria to proceed to Simon's stage 2. A total of 22 patients in the HNSCC will be enrolled. VV1 plus cemiplimab shows promise in first line R/M HNSCC based on these initial results. Clinical trial information: NCT04291105 . Patient demographics. N (treated) 10 Sex 20% female Median age (y) 60 (54 – 76) Oropharynx 7 HPV+ 7 Oral cavity 3 PD-L1 CPS median (range) 7.5 (1-45%) Locoregional injection 3 Distant injection 6 Local and distant injection 1 Best response (RECIST 1.1) PR 3 SD 5 PD 2 Adverse Events #pts any VV1/cemiplimab-related G3 AE 4 Lymphopenia 3 Elevated ALK 1
Staffing, accepted indications, and dose of Phase II cardiac rehabilitation: country income class and time-based comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s (ICCPR) 2025 Audit Update
Mampuya, Warner , Jiandani, Mariya P , Mbau, Lilian, Rivero, Monserrat Cruz , Anchique, Claudia V. , 丁荣晶 , Schalkwijk, Dinah L. van , Gallagher, Jonathan , Fernández, Rosalia, Maskhulia, L , Martinez, Jimena, Botha, Noel V Hau, Champaiboon, Jirapa , Yokoyama, Miho, Investigators, ICCPR Global Cardiac Rehabilitation Audit Update, Akinci, Buket, Carson, Rachael Pamela, Quesada-Chaves, Daniel F, Norekvål, Tone M, Kouidi, Evangelia , Таргыновна, Аймакова Гульсим, Quito, Benjamin Jose, Lima de Melo Ghisi, Gabriela , Turk-Adawi, Karam , Mampuya, Warner M , Jiandani, Mariya P , Mbau, Lilian , Cruz Rivero, Monserrat , Anchique, Claudia V , Gallagher, Jonathan , Gaye, Ngone Diaba , Kim, Won-Seok , Seron, Pamela , Maskhulia, Lela , Batalik, Ladislav , Chen, Ssu-Yuan , Supervía, Marta , Champaiboon, Jirapa , Grace, Sherry L , Mettananda, Chamila Dinushi Kukulege , Baťalík, Ladislav , Yokoyama, Miho Nishitani , Grace, Sherry L. , Akıncı, Buket , Candelaria, Dion , Quesada-Chaves, Daniel, Norekvål, Tone M. , Szadkowska, Iwona , Jug, Borut , Aimakova, Gulsim T., Radi, Basuni

Mayo Clinic

European Journal of Preventive Cardiology | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag292 | PMID 42207983 Get It

Abstract Aims To characterize global variation in cardiac rehabilitation (CR) staffing, indications, and prescribed dose by country income classification and compare findings with the International Council of Cardiovascular Prevention and Rehabilitation’s 2016 Global Audit. Methods and results Cross-sectional REDCap survey of Phase II/post-discharge CR programmes (May–September 2025). Outcomes were multidisciplinary team size/composition, accepted cardiac and non-cardiac indications, and centre-based CR dose. Comparisons were made across World Bank country income classifications and Audit decade (2016 vs. 2025). Of 7025 programmes identified globally, 1505 (median programme response rate = 62%/country) initiated a survey, from 90/113 (80%) countries with CR. CR was delivered by a multidisciplinary team of 7 (median; P25–P75 = 5–8; nurses, physiotherapists, cardiologists, and dietitians most common); teams were smaller in low-income countries (median = 4; P &lt; 0.001), and physician specialty varied. Non-low-income programmes consistently accepted (≥90%) patients with acute coronary syndrome, with programmes in low-income countries less often accepting related interventions (e.g. surgery: low-income 0% vs. high-income 97%; P &lt; 0.01), but non-cardiac indications were more frequently accepted (e.g. primary prevention, diabetes, and lung disease). Acceptance of heart failure increased compared with the previous Audit (70% vs. 87%; P &lt; 0.001). Centre-based programmes prescribed a median of 20 h (P25–P75 = 12–30), typically two sessions/week over 8 weeks. Globally, 65 (72%) countries prescribed a median ≥12 sessions/programme. Programmes in upper-middle-income countries prescribed more sessions (median = 24, P25–P75 = 12–36; P &lt; 0.001). Dose did not differ meaningfully between Audits (P = 0.07). Conclusion CR programmes globally are offered by small, but multidisciplinary teams. They accept guideline-indicated patients, with applicable variation by context. Insufficient dose in one-quarter of countries underscores investment need.
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-
Bansal, Ajay, Stoffel, Elena M., Lim, Ramona , Burke, Carol, Hall, Michael J., Singh, Aparajita , Boardman, Lisa A., Samadder, Niloy Jewel, Ballestar, Veroushka, Muller, Charles, Scott, Aaron J. , Xu, Yanfei , Eickhoff, Jens, Meredith, Hyun, Aquila, Lanni , Szabó, Éva , Della’Zanna, Gary , Bengtson, Lisa, Schlom, Jeffrey, Donahue, Renee N., Horn, Lucas A., Palena, Claudia, Gulley, James L., Samaddar, Sohini, Moore, Dennis F., Sharma, Parth, Madan, Rashna , Hurley, Karen, Soon‐Shiong, Patrick , Gabitzsch, Elizabeth, Sender, Lennie, Brenner, Dean, Schuetze, Scott, Djuric, Zora, Barroilhet, L. E., Thompson, Patricia, Bauman, Julie, Khan, Seema, Vilar, Eduardo, Szabo, Eva , Stoffel, Elena M. , Stanich, Peter P. , Patel, Swati , Burke, Carol A. , Hall, Michael J. , Muller, Charles , Benante, Kelly A. , Eickhoff, Jens C. , Zaborek, Jen , Umar, Asad , Richmond, Ellen S. , Schlom, Jeffrey , Donahue, Renee Nicole , Toney, Nicole J. , Palena, Claudia , Gulley, James L , Moore, Dennis F., Djurić, Zora , Barroilhet, Lisa , Vilar, Eduardo

Mayo Clinic

Frontiers in Immunology | May 19, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1809281 | PMID 42238576 Get It

Introduction Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers. Methods In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity. Results All 20 SP participants (median age 57.5 (range 42–75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual. Discussion In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. Clinical Trial Registration https://clinicaltrials.gov/study/ , identifier NCT05419011.